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ABSTRACT: Background: Commentators suggest
that patients have unrealistic expectations about the
pace of research advances and that such expectations
interfere with patient decision-making.
Objective: The objective of this study was to compare
expert expectations about the timing of research mile-
stone attainment with those of patients who follow
Parkinson’s disease (PD) research.
Methods: Patients with PD and experts were asked to pro-
vide forecasts about 11 milestones in PD research in an
online survey. PD experts were identified from a Michael
J. Fox Foundation database, highly ranked neurology cen-
ters in the United States and Canada, and corresponding
authors of articles on PD in top medical journals. Patients
with PD were recruited through the Michael J. Fox Founda-
tion. We tested whether patient forecasts differed on average
from expert forecasts. We also tested whether differences
between patient forecasts and the average expert forecasts
were associated with any demographic factors.
Results: A total of 256 patients and 249 PD experts com-
pleted the survey. For 9 of the 11 milestones, patients’
forecasts were on average higher than those of experts.
Only exercise therapy met our 10% difference threshold
for practical significance. Education was the only demo-
graphic that predicted patient deviations from expert fore-
casts on milestone forecasts. Patients offered significantly
higher forecasts than experts that the clinical trials used in
milestone queries would report positive primary outcomes.
Conclusions: Differences between patient and expert
expectations about research milestones were generally
minor, suggesting that there is little cause for concern that
patients who follow PD research are unduly swayed by
inaccurate representations of research advancement in the
media or elsewhere. © 2020 The Authors. Movement Disor-
ders published by Wiley Periodicals LLC. on behalf of Inter-
national Parkinson and Movement Disorder Society.
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Because of the slow and inexorable progression of
Parkinson’s disease (PD), many patients with PD are
keenly interested in emerging treatment strategies. How-
ever, the quality of information available to patients var-
ies. Media coverage of emerging treatment approaches
such as stem cell therapy1–6 or repurposed drugs7 have
often overstated the promise and understated the chal-
lenges for developing new treatments. Such representa-
tions may foster unrealistic expectations in patients8,9
that can frustrate informed consent, clinical trial recruit-
ment, or interfere with patient decision-making.10,11
Despite the very large literature on media representa-
tions of medical advances, little is known about how well
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patient perceptions of the promise and timelines for
development of new treatments align with those of
experts. Many studies suggest that patients who enroll in
clinical trials harbor higher expectations of direct benefit
than the physicians running the trials (“therapeutic over-
estimation”).12,13 However, such studies cannot distin-
guish between different interpretations of probabilistic
statements offered by patients.14–16 Nor does this body
of literature offer a clear picture on patient perceptions
of medical advance more generally.17
Medical and research communities have important
responsibilities to communicate to patient communities
their expectations about the promise and prospects of
emerging treatments. Ideally, such communications
should enable motivated patients to have a reasonable
grasp of the maturity of new treatment paradigms so
that patients can more effectively plan their current and
future care.
We therefore undertook a study that solicited fore-
casts from patients with PD and experts about timelines
for the attainment of 11 different PD research mile-
stones. We then assessed the extent to which patient
expectations aligned with those of experts.18
Methods
Expert and PD Patient Sample
Patients with PD were recruited to the survey through
the Michael J. Fox Foundation for Parkinson’s Disease
Research (MJFF) e-mail list. To minimize survey burden,
each e-mail address was solicited by email once for par-
ticipation. Because the MJFF e-mail list contains both
patients with PD and nonpatients, our survey responses
contained both patient and nonpatient responses. For
the purposes of this study, we removed the nonpatient
responses from our sample to focus solely on patient per-
ceptions. We report an analysis with all of the responses
per our preregistration in Supplemental Material S1.
PD experts were recruited in the following 3 ways:
(1) the MJFF database of experts, (2) the identifcation of
doctors specializing in PD at the 25 neurology depart-
ments in the United States receiving top rankings in US
News and World Report 2018 and 3 highly regarded
hospital systems in Canada, and (3) the identifcation of
corresponding authors of articles on PD from the past
5 years in 10 top general and neurology/movement dis-
order journals. Experts were solicited by email 3 times.
Survey
Milestones in PD research were generated by R.B.,
A.L., and T.S., seeking milestones whose attainment
would be objectively verifiable, diverse, and thought to
be of interest to the patient community (see Kane and
colleagues18 for details). For milestones dealing with
trial launches or enrollments, we asked for a prediction
of whether the trial would be positive on a primary out-
come. The survey was administered via Qualtrics.
Expert versions of the milestones and survey wording
are provided in Table 1.
The patient survey was created in collaboration with
the MJFF research communications directors by replacing
jargon terms from the expert survey with more accessible
language and providing background information on the
context of why each milestone was important.
Our survey sought forecasts for milestone attainment
in 4 time bins (next 2 years, 4–6 years, 6–10 years, and
longer than 10 years). We expected the richness of this
elicitation, in particular asking about all possible future
time periods in which a milestone could occur, to limit
the effects of various biases and ambiguities associated
with simpler survey approaches. For the questions
about the outcomes of clinical trials we used a simpler
elicitation format where participants just indicated the
probability of a positive outcome.
A preliminary run of the survey was conducted in
October 2018 with 50 experts and 50 patients to test
our distribution platforms. The full surveys were run in
January 2019 (patients) and between January and April
2019 (experts).
Preprocessing of Forecasts
This survey was designed primarily to test the effect
of aggregation techniques on forecast accuracy in the
context of PD, the results of which will be reported in
coming years. The present study was planned as a sec-
ondary objective. Adjusting forecasts obtained for the
primary objective to enable analyses for this secondary
objective required preprocessing for the present analysis
(eg, converting 4 time bins into 2: the probability of
each milestone occurring or not occurring in the next
6 years). Details of the preprocessing are reported in
Supplemental Material S1.
Analysis
Our primary analysis was a 2-sided bootstrapped
t test comparing the average expert forecast of the mile-
stone occurring in the next 6 years to the average
patient forecast of the same for each milestone. We
applied a Bonferroni correction to the individual mile-
stone tests. After we had analyzed the expert data, but
before analyzing the patient data, we defined a differ-
ence of 10% between patient and expert average fore-
casts as representing a meaningful difference in
expectation. This threshold was based on our assump-
tion that differences smaller than 10% would have little
practical impact on patient decision-making given the
presence of other influences. We also applied this analy-
sis to the additional questions about trial results.
As an exploratory analysis, we fitted a regression
model to test whether any demographic variables
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predicted higher forecasts. For each forecast, we first
subtracted the average expert forecast for the associated
milestone. We then regressed this difference on age,
gender, and education along with milestone controls.
Education was coded as a factor with levels: high
school, bachelor’s, master’s, doctor of medicine, doctor
TABLE 1. List of milestones used in our survey
Topic Event Full Description Additional Patient Text
Monogenic gene
therapy
US FDA approval The US FDA approves a gene therapy directed at
a monogenic cause of PD such as LRRK2,
GBA, or parkin for treatment of PD.
Gene therapy is a technique that modifies a




Trial enrollment; results A rigorous phase 2 or phase 3 clinical trial PD
that specifies eligibility based on GBA
mutational status successfully enrolls at least
80 subjects.
GBA is the most commonly mutated gene in
people with PD. The GBA mutation
appears in between 5% and 10% of
patients with PD.
Cell therapy Trial initiation; results The launch of a rigorous phase 2 or phase 3
clinical trial involving implantation of patients
with PD with dopaminergic cells derived from
pluripotent stem cells.
PD causes loss of dopamine producing cells
in the brain (dopaminergic cells).
Scientists believe that new dopaminergic
cells grown from stem cells could 1 day
restore normal dopamine levels in the
brains of patients with PD.
Imaging Trial initiation; results A selective α-synuclein imaging agent is
integrated into a rigorous PD interventional
clinical trial.
α-synuclein is a protein believed to play a
key role in PD progression. Scientists are
developing an “imaging agent” to measure
α-synuclein in the brain, which could be
used when testing PD treatments.
Deep brain
stimulation
US FDA approval US DA approval of the first closed-loop deep
brain stimulation device for the management
of PD.
Scientists are trying to develop “smart” deep
brain stimulation devices that can
modulate their stimulation based on a




Trial initiation; results Launch of a rigorous phase 3 clinical trial testing
a novel, noncholinesterase inhibiting drug in
the treatment of PD-MCI.
MCI—changes in memory or cognition that
do not interfere with daily life—is
common in PD. It is usually treated with a
class of drugs called cholinesterase
inhibitors. Scientists are trying to discover
better drugs for treating MCI.
Drug
repositioning
Trial results A rigorous phase 3 clinical trial using a
repositioned medication and aimed at slowing
the progression of PD symptoms reports a
positive outcome on a primary efficacy end
point.
Sometimes drugs known to work for certain
diseases (eg, cancer) are discovered to
work against other diseases (eg, multiple
sclerosis). When a drug is used to treat
multiple diseases this way it is referred to
as a “repurposed” drug.
Exercise therapy Trial results A rigorous phase 2 or phase 3 clinical trial
testing the effect of exercises, physical
activity, or physical therapy on PD progression







An algorithm derived from a body worn sensor is
accepted by the International Parkinson and
Movement Disorder Society as a valid
measure of PD symptoms.
Scientists are testing body worn sensors for




Breakthrough of the Year
Science magazine awards “Breakthrough of the
Year” to a molecule, process, cell, or
discovery that is expressly described, in the
accompanying Science article, as implicated in
PD pathogenesis or possible treatment.
None
Immunotherapy Trial results A rigorous phase 2 or phase 3 clinical trial
testing an alpha-synuclein based
immunotherapy for PD reports a positive
outcome on a primary efficacy end point.
α-synuclein is a protein believed to play a
large role in PD progression. Scientists are
trying to develop an “immunotherapy” that
allows the immune system to target
α-synuclein and block its harmful effects.
Additional clarifying details for some of the milestones were listed as footnotes (see Supplemental Material S1 for details).
US FDA, US Food and Drug Administration; PD, Parkinson’s disease; MCI, mild cognitive impairment.
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of medicine/doctor of philosophy, and doctor of philos-
ophy. The questions about trial results were not
included in this analysis.
Our survey received approval by the McGill institu-
tional review board; participants provided consent
online. This analysis was preregistered after the survey,
and some preliminary analysis of the expert forecasts
was completed (but before any analysis of the patient
forecasts) and can be found on the Open Science Frame-
work at https://osf.io/3zcws/?view_only=b008d83777
e24c16a7768ffbde92ab0a. Our primary analysis was
modified following suggestions by Movement Disorders
peer reviewers (our unmodified analysis can be found in
Supplemental Material S1; the changes made do not
alter the substantive pattern of conclusions).
Results
Properties of Forecaster Samples
The survey was completed by 256 patients with PD of
13,896 lay people solicited (response rate is impossible
to estimate because we do not know what proportion of
the invitations were received). The survey was also com-
pleted by 63 lay people who were not patients with
PD. The patient sample was 43% female; median age of
respondents was 68 years (range 38–90); the highest
degrees held by our respondents were high school
(18%), bachelor’s (36%), master’s (29%), doctor of
medicine (3%), doctor of medicine/doctor of philosophy
(2%), doctor of philosophy (10%). The survey was com-
pleted by 249 experts in PD as previously described.18
Properties of Forecasts
Figure 1 displays the forecasts for each milestone for
patient and expert participants. Table 2 contains the
means and standard deviations of forecasts for each
milestone for both the patient and expert participants as
well as P values for bootstrapped t tests. On average,
patients and experts both tended to offer higher forecasts
for milestones related to disease management and diag-
nostics (eg, body worn sensors) than more experimental
therapies (eg, gene therapy, stem cell therapy). In accor-
dance with experts, patients rated the monogenic disease
gene therapy milestone as the least likely to occur, but in
contrast with experts, they rated the exercise therapy
milestone as the most likely to occur. The variance of
forecasts was similar for both groups with the distribu-
tion of forecasts covering almost the entire range of pos-
sible values for each milestone, indicating a diversity of
expectations among both experts and patients. Overall,
the distributions appear similar, although patients pro-
vided generally higher forecast probabilities, with the
patient average being higher than the expert average for
9 of the 11 milestones.
For our primary analysis, we observed a statistically
significant difference in forecasts for several milestones
(Table 2). However, only the exercise therapy milestone
met our predefined level of practical significance of
10%. All of the additional questions about trial results
showed statistically significant differences in expecta-
tions and met our benchmark for practical significance.
Analysis of Relationship Between Higher Lay
Forecasts and Demographic Information
In our exploratory analysis, neither age (t = −1.20,
P = 0.23) nor gender (t = −1.73, P = 0.08) provided
significant increases in the fitting of the data. Only
education provided a significant increase in fit
(F2724,5 = 9.98, P < 0.001), with patients having only a
bachelor’s degree offering the highest forecasts of mile-
stone attainment followed by those with only a high
school diploma, and those holding postgraduate
degrees offering the lowest forecasts. Estimates of the
coefficients and 95% confidence intervals are pres-
ented in Table 3.
FIG 1. Violin plots of the dichotomized lay and expert forecasts for each milestone. PD-MCI, Parkinson’s disease–mild cognitive impairment.
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Discussion
Patients’ forecasts about the attainment of major PD
research milestones within 6 years were significantly
and consistently higher than those of experts. However,
misalignment was modest in magnitude. For only
1 milestone—exercise therapy—differences met our
prespecified criterion of practical significance. Excep-
tionally high forecasts for exercise therapy may reflect
the fact that many patients with PD have direct and
positive experience with exercise, including that it is
readily available and lacks major adverse effects.
Our finding that patients with graduate degrees
tended to provide forecasts that were more in line with
experts is consistent with previous work showing a
relationship between low educational attainment and
phenomena such as therapeutic misestimation.13,19 We
also observed significant variation in the judgments of
both patient and experts, with many patients offering
low probabilities and many experts offering high prob-
abilities. This could suggest that patients have views
that align more or less with expert opinion. However, it
also raises the possibility that patients may be unduly
influenced by physicians with extreme views.
Our core findings might be explained in several ways.
First, if one accepts the premise that experts on average
maintain an accurate read of the future, patients may
harbor mildly unrealistic positive expectations about
milestone attainment. Second, some patient expecta-
tions we captured may represent an expression of a
hopeful attitude rather than purely probabilistic
estimates.14–16 Third, higher patient forecasts could sig-
nal greater patient uncertainty about the timing of mile-
stone attainment. We note that for many milestones,
patient forecasts were closer to 50% than expert
forecasts.
In contrast to the milestone forecasts, patients offered
significantly and meaningfully higher forecasts about
positive trial outcomes than experts. This may reflect a
lack of experience with how often clinical trials report
null results. Such high probabilities would be consistent
with patients tending to overestimate the probability of
benefit associated with trial participation.12,13 Higher
trial outcome forecasts could also be an artifact of the
simpler format by which the trial result forecasts were
obtained.
Our study has several limitations. We focused on spe-
cific milestones to ensure that these predictions were
verifiable for a future study assessing accuracy. This
emphasis on verifiability meant that our questions
excluded other important research milestones. More-
over, we selected milestones that, at the outset, had
TABLE 2. Means and SDs for probability of the milestone occurring in the next 6 years for each milestone for patients and
experts
Milestone Lay Mean (SD) Expert Mean (SD) P Value
Monogenic gene therapy 33.85 (22.49) 27.26 (20.39) <0.001*
Precision medicine therapy 49.38 (25.50) 52.83 (26.73) 0.13
Cell therapy 42.64 (25.37) 40.00 (24.52) 0.23
Imaging 50.52 (23.98) 44.00 (24.74) 0.002*
Deep brain stimulation 48.39 (24.39) 50.77 (26.16) 0.29
Treatment for PD-MCI 45.79 (23.55) 45.06 (23.85) 0.73
Drug repositioning 48.73 (24.48) 39.60 (23.24) <0.001*
Exercise therapy 63.65 (25.27) 52.77 (25.63) <0.001*
Body worn sensors 56.75 (25.40) 55.34 (26.51) 0.54
Basic science discovery 39.82 (24.55) 37.28 (24.24) 0.24
Immunotherapy 44.62 (23.16) 36.94 (24.75) <0.001*
Precision medicine therapy result 56.22 (27.63) 44.73 (24.90) <0.001*
Cell therapy result 58.71 (29.07) 39.73 (26.87) <0.001*
Imaging result 62.79 (21.17) 49.53 (26.41) <0.001*
Treatment for PD-MCI result 59.56 (27.17) 39.90 (24.08) <0.001*
The last 4 rows represent the questions about trial results. Kendall’s τ for the patient and expert averages was 0.64, indicating moderate agreement on the rank
order of milestones.
SD, standard deviation; PD, Parkinson’s disease; MCI, mild cognitive impairment.
TABLE 3. Coefficient estimates and 95% confidence
intervals for our regression of relative patient forecasts and
their deviation from average expert forecasts by lay person
age, gender, education, and PD status, along with
milestone controls
Variable Coefficient Estimate 95% Confidence Interval
Age −0.07 −0.18 to 0.04
Gender (male) −1.65 −3.51 to 0.20
Education (bachelor’s) 3.87 1.35 to 6.40
Education (master’s) −2.83 −5.48 to −0.15
Education (MD) −5.79 −11.3 to −0.22
Education (MD/PhD) −4.28 −10.96 to 2.33
Education (PhD) −4.20 −7.67 to −0.64
The estimates for the milestone controls are omitted.
PD, Parkinson’s disease; MD, doctor of medicine; PhD, doctor of
philosophy.
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some prospects of materializing within 10 years. The
use of milestones that are widely regarded by experts as
highly unlikely to occur within 10 years, such as the
reversal of many PD disease features via stem cells,
might have led to larger differences in expectations. Sec-
ond, forecasts are sensitive to elicitation platforms.
Although our preprocessing procedure likely blunted
some effects of innumeracy, our question format may
have interacted with opinions. Last, selection bias is
always a concern in surveys of this nature. Our patient
sample was enriched for highly informed and engaged
patients. Indeed, participants were identified not from
clinics but, rather, because they subscribe to electronic
alerts from a major research foundation. Our sample
was more educated generally and more informed about
PD specifically than would be a random sample of
patients with PD.20
Our study investigated attitudes about broad lines of
research rather than beliefs about specific clinical trials.
It thus marks a contrast with previous work on patient
expectations in clinical research.12,13 The fact that
patient forecasts did not exceed those of experts by
large amounts across a wide frontier of innovation is
inconsistent with a common perception that patients
uncritically absorb exuberant media reports or com-
mercial claims. Indeed, our findings of alignment are
consistent with research suggesting that even patients
with PD seeking out unproven interventions tend to
harbor very modest and skeptical expectations about
benefits for unproven treatments.21,22 Nevertheless, we
did observe greater misalignment for patients with
lower education attainment compared with those with
graduate degrees. We also observed higher expectations
about trials producing positive results on their primary
end points. This last finding, although a secondary out-
come of our study and in need of replication, is poten-
tially concerning because it may bear on patient
consent to trial enrollment. Many promising PD treat-
ments have produced null results when tested in ran-
domized trials, and recent meta-analyses suggest that
there is no medical advantage to being assigned to
treatment arms in placebo-controlled trials involving
neurodegenerative diseases.23 Our findings suggest that
many patients may not appreciate that randomized tri-
als in PD begin with a credible and honest null hypoth-
esis. Physicians, professional societies, and patient
advocacy organizations might better explain to patients
and patient communities that even PD treatments
backed by sound preclinical and early-phase evidence
have a low prior probability of demonstrating efficacy
in randomized trials.
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